Abingdon Health (ABDX.L)

Executive Summary

Abingdon Health is a leading UK-based contract development and manufacturing organization (CDMO) specializing in lateral flow tests for in-vitro diagnostics and companion diagnostics. With facilities in the UK and US, the company offers end-to-end services from development to regulatory support, targeting healthcare, animal health, and plant health sectors. Despite a small market cap of approximately £30.7 million, Abingdon Health is well-positioned in the growing rapid testing market, driven by increasing demand for decentralized diagnostics and point-of-care testing. The company's proprietary platform and expertise in complex lateral flow assays provide a competitive advantage, though profitability remains volatile with historical losses. Recent strategic initiatives, including US expansion and partnerships, aim to diversify revenue and improve margin profile. The outlook hinges on securing larger contracts and scaling manufacturing capacity.

Upcoming Catalysts (preview)

• Q3 2026Major CDMO Contract Win with Pharmaceutical Partner60% success
• Q4 2026Regulatory Approval (CE-IVDR or FDA) for a Lateral Flow Test Developed In-House50% success
• Q2 2026Capacity Expansion or New Facility Opening in the US70% success